

Supplementary

Table S1 Clinical staging and corresponding levels of CEA and CA19-9 before and after neo-CRT

Clinical staging [§]	Number of cases (n=197)	CEA (+)		CA19-9 (+)	
		Baseline, n=84 (42.6%)	After neo-CRT, n=19 (9.6%)	Baseline, n=21 (10.7%)	After neo-CRT, n=5 (2.5%)
cT2	16 (8.1%)	2 (2.4%)	3 (15.8%)	2 (9.5%)	1 (20%)
cT3	160 (81.2%)	71 (84.5%)	15 (78.9%)	17 (81.0%)	3 (60%)
cT4	21 (10.7%)	11 (13.1%)	1 (5.3%)	2 (9.5%)	1 (20%)
cN0	23 (11.7%)	8 (9.5%)	3 (15.8%)	3 (14.3%)	0 (0%)
cN1	96 (48.7%)	31 (36.9%)	6 (31.6%)	10 (47.6%)	3 (60%)
cN ₂	78 (39.6%)	45 (53.6%)	10 (52.6%)	8 (38.1%)	2 (40%)

§, clinical restaging after neo-CRT was evaluated by enhanced pelvic MRI. CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; neo-CRT, neoadjuvant chemoradiotherapy. CEA (+): CEA >5 ng/mL, CA19-9 (+): CA19-9 >37 IU/mL.